SOURCE: Alzheimer's Drug Discovery Foundation

August 12, 2008 14:54 ET

The Latest Trends and Research for Drug Discovery in Alzheimer's Disease

NEW YORK CITY, NY--(Marketwire - August 12, 2008) - The Alzheimer's Drug Discovery Foundation (ADDF) announces the 9th International Conference on Alzheimer's Disease Drug Discovery, October 6-7, 2008 at The Westin New York at Times Square. This scientific conference's unique focus is solely on the discovery and development of innovative drugs for Alzheimer's disease and related dementias.

Thirty leading international experts from academia and early stage biotechnology companies will discuss and present their most current research on the following topics: Neuroprotection, Anti-Amyloid & Misfolding, Anti-Tangles, Anti-Inflammatory and Anti-Oxidant Strategies. The meeting is designed for academic and industry scientists engaged in drug discovery research for neurodegenerative diseases; business development and licensing professionals; alliance management professionals; venture capitalists and other investors.

"The latest developments in basic neuroscience and pre-clinical research are rapidly bringing us closer to important and practical applications," said conference Chair Howard Fillit, MD, Executive Director with the ADDF. "Once more, we are proud to bring this important event to the worldwide community of researchers as we continue ADDF's mission to accelerate the discovery of novel, disease-modifying treatments for Alzheimer's disease."

Discussions will highlight current trends in research, new targets and novel early-stage programs. Ample opportunity for networking will also be possible for establishing collaborations and licensing opportunities.

The conference is being made possible through the generous support of Allon Therapeutics Inc., Baxter Biosciences, Bellus Health Inc., Elan Pharmaceuticals, Inc., Forest Research Institute, Genentech Inc., JSW-Research Forschungslabor GmbH and Wyeth Research.

For general inquiries, contact:

CALENDAR EDITORS: Please list this meeting in your publication's calendar.

About the Alzheimer's Drug Discovery Foundation (ADDF)

The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity established in 2004 to expand upon the programs initiated by the Institute for the Study of Aging (ISOA), a private foundation founded by the Lauder family in 1998. Our mission is to accelerate drug discovery research for Alzheimer's disease, cognitive aging and related dementias through venture philanthropy. To date, ADDF and ISOA have jointly awarded $33 million for 244 research programs and conferences worldwide. For more information, visit

Contact Information